FUZEON
Generic Name for FUZEON
Enfuvirtide 90mg/mL; pwd for SC inj after reconstitution; preservative-free.
Legal Classification:
Rx
Pharmacological Class for FUZEON
Fusion inhibitor.
Manufacturer of FUZEON
Roche Laboratories
|
Indications for FUZEON
Treatment of HIV-1 infection, in combination with other antiretroviral agents, in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy.
Adult dose for FUZEON
Give by SC inj into upper arm, anterior thigh, or abdomen (not into moles, scar tissue, bruises, or navel). ≥16yrs: 90mg twice daily. Rotate inj sites.
Children's dosing for FUZEON
6–16yrs: limited data available; doses of 2mg/kg (max 90mg) twice daily have been used.
Warnings/Precautions for FUZEON
Discontinue if hypersensitivity occurs; do not rechallenge. Monitor for pneumonia (esp. if low initial CD4 cell count, high initial viral load, or smoker). Renal insufficiency (CrCl <35mL/min). Supervise 1st dose. Pregnancy (Cat.B). Nursing mothers: not recommended.
Interactions for FUZEON
May cause false (+) ELISA test for HIV.
Adverse Reactions for FUZEON
Inj site reactions, diarrhea, nausea, fatigue, insomnia, infections (eg, bacterial pneumonia), peripheral neuropathy, pancreatitis, hypersensitivity reactions (eg, rash, fever, GI upset, elevated ALT/AST, eosinophilia), lab abnormalities (eg, elevated amylase).
Notes for FUZEON
Register pregnant patients exposed to enfuvirtide by calling (800) 258-4263.
How is FUZEON supplied?
Kit—1 (60 vials w. supplies)
Related Disease:
HIV~antivirals